FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next >>
 
TXT Remote Interactive Evaluation Guidance
10/25/2023
 
 
TXT Medinol Gets OK on Latest Drug-Eluting Stent
10/25/2023
 
 
TXT FDA Decision on Florida Drug Imports Delayed: Report
10/25/2023
 
 
TXT Akebia Refiles Kidney Disease NDA
10/25/2023
 
 
TXT ‘Positive Results’ from BioXcel Data Audit
10/25/2023
 
 
TXT Califf Positive on Visit to India
10/25/2023
 
 
TXT Dermatologic Corticosteroid BE Guidance
10/25/2023
 
 
TXT FDA Approves New Tibsovo Indication
10/24/2023
 
 
TXT UCB Farchim FDA-483 Released
10/24/2023
 
 
TXT FDA Changes Off-Label Approach: Attorney
10/24/2023
 
 
TXT ResMed Recalls Astral 100, 150 Ventilators
10/24/2023
 
 
TXT FDA Accepts sBLA for Self-Administered FluMist
10/24/2023
 
 
TXT Predetermined Change Control Plan Principles
10/24/2023
 
 
TXT Embryll Marketing Unapproved Animal Drug: FDA
10/24/2023
 
 
TXT FDA Clears NKGen IND for Alzheimer’s Cell Therapy
10/24/2023
 
 
TXT Genentech’s Rozlytrek Gets Expanded Use
10/24/2023
 
 
TXT Guide on Scientific Info on Unapproved Uses
10/23/2023
 
 
TXT FDA Approves Zymfentra as Maintenance Therapy
10/23/2023
 
 
TXT Panacea Biotec Gets 9-item FDA-483
10/23/2023
 
 
TXT Complete Response on Dupixent sBLA
10/23/2023
 
 
TXT Medtronic Warning on McGrath Video Laryngoscopes
10/23/2023
 
 
TXT Keytruda ‘Positive’ Data in Cervical Cancer
10/20/2023
 
 
TXT Pfizer Pentavalent Meningococcal Vaccine Approved
10/20/2023
 
 
TXT Philips Respironics Recalls V60 Ventilators
10/20/2023
 
 
TXT Arrest Made in Misbranded Device Case
10/20/2023
 
 
TXT BioMarin Expanded Indication for Voxzogo
10/20/2023
 
 
TXT FDA Updates AI/ML-Enabled Medical Device List
10/19/2023
 
 
TXT Untitled Letter for India’s Nectar Lifesciences
10/19/2023
 
 
TXT OCE Scientific Collaborative Research Areas
10/19/2023
 
 
TXT Final Guide on Remote Monitoring Devices
10/19/2023
 
 
TXT Hygienic Labs Didn’t Respond to FDA Data Requests
10/19/2023
 
 
TXT BMS Seeking Approval of Subcutaneous Opdivo
10/19/2023
 
 
TXT Confusion Exists in RWD/RWE Definitions: Analysis
10/19/2023
 
 
TXT Regenerative Medicine Consensus Standards Guide
10/19/2023
 
 
TXT Guide on Drug, Biologic Benefit/Risk Assessment
10/18/2023
 
 
TXT SeaStar Breakthrough Status for Cytopheretic Device
10/18/2023
 
 
TXT Courts Could Cut FDA Labeling Enforcement: Avorn
10/18/2023
 
 
TXT FCA Cases Look at Cybersecurity: Attorneys
10/18/2023
 
 
TXT BrainStorm Pulls NurOwn BLA
10/18/2023
 
 
TXT Non-Invasive Monitoring Enforcement Guide
10/18/2023
 
 
TXT FDA Clears Intellia IND for Phase 3 Trial
10/18/2023
 
 
TXT Praxis 510(k) for Biopsy Device Cleared
10/17/2023
 
 
TXT Keytruda OK’d Before/After Lung Cancer Surgery
10/17/2023
 
 
TXT ‘Is Chevron Deference Dead?’: Ex-FDAer Pitts
10/17/2023
 
 
TXT Guilty Plea in SphenoCath Case
10/17/2023
 
 
TXT FDA Wants Comments on Innovative Clinical Trials
10/17/2023
 
 
TXT Verrica Asks FDA to End Ycanth Compounding
10/17/2023
 
 
TXT 6 Observations in Samsung Biologics FDA-483
10/17/2023
 
 
TXT FDA Denies UCB Generic Fintepla Petition
10/17/2023
 
 
TXT Providence Medical Tech Cavux Facet Device Cleared
12/16/2022
 
 
TXT FDA OK’s Ferring’s Bladder Cancer Gene Therapy
12/16/2022
 
 
TXT Panel to Examine Ongoing Covid Vaccine Modifications
12/16/2022
 
 
TXT Contractor Conflict-of Interest Bill Passes Congress
12/16/2022
 
 
TXT Aurigene Ditches Psoriasis Drug Candidate
12/16/2022
 
 
TXT Draft Guide on Pulmonary Tuberculosis Drugs
12/15/2022
 
 
TXT Draft Inspection Refusal Guidance
12/15/2022
 
 
TXT FDA Stem Cell Therapy Regulation at Risk: Attorneys
12/15/2022
 
 
TXT FDA Updates CRL Guidance Performance Goals
12/15/2022
 
 
TXT Comments on Immune-Mediated Adverse Reaction Guidance
12/15/2022
 
 
TXT Independent FDA Needed to Stop Political Meddling: GAO
12/15/2022
 
 
TXT Harmonize Innovative Manufacturing Regulation: PhRMA
12/14/2022
 
 
TXT AdvaMed Supports Breakthrough Device Guidance Updates
12/14/2022
 
 
TXT VALID Could Hurt Home Sample Testing: Attorneys
12/14/2022
 
 
TXT Former NECC Ops Director Sentenced to 5 Months in Jail
12/14/2022
 
 
TXT FDA Panel Thumbs Down on Heart Failure Drug
12/14/2022
 
 
TXT States Pushing for Canadian Drug Imports: Report
12/14/2022
 
 
TXT FDA Accepts NDA for Eye Dilating Combo Product
12/13/2022
 
 
TXT $2.25 mil. RWD Funding Opportunity
12/13/2022
 
 
TXT CGMP Deviations Seen in Centrient Inspection
12/13/2022
 
 
TXT Clinicians Need Refresher on Clinical Trial Statistics: Survey
12/13/2022
 
 
TXT What’s Behind the New LASIK Guidance?
12/13/2022
 
 
TXT Assign TE Codes for All Approved Drugs: Study
12/13/2022
 
 
TXT Change Antibiotic Development Incentives: Study
12/13/2022
 
 
TXT Moderna/Merck Cancer Vaccine Meets Endpoint
12/13/2022
 
 
TXT Doc Group Wants FDA Probe of Musk’s Neuralink
12/13/2022
 
 
TXT Smiths Device Correction on CADD Infusion System
12/12/2022
 
 
TXT CVM Sees 1% Decrease in Food Animal Antimicrobial Use
12/12/2022
 
 
TXT Academics Urge FDA to Simplify Breast Density Notifications
12/12/2022
 
 
TXT DoJ Indictment on Unapproved Drugs
12/12/2022
 
 
TXT Panel Meeting to Discuss Isotretinoin iPLEDGE REMS Program
12/12/2022
 
 
TXT FDA Hits 2 QuVA Pharma Facilities with 483s
12/12/2022
 
 
TXT Academics Urge Tougher FDA Stance on Accelerated NDAs
12/09/2022
 
 
TXT Device Voluntary Malfunction Summary Reporting Guide
12/09/2022
 
 
TXT Remel Recalls Thermo Scientific Sensititre Plates
12/09/2022
 
 
TXT Janssen Files BLA for Myeloma Therapy
12/09/2022
 
 
TXT 2 Roche Alzheimer’s Tests Cleared by FDA
12/09/2022
 
 
TXT 10 Observations in Aurobindo Unit FDA-483
12/08/2022
 
 
TXT Non-Device Software Function Report
12/08/2022
 
 
TXT Draft VMSR Guidance for Manufacturers
12/08/2022
 
 
TXT 16 Observations on Lupin Unit FDA-483
12/08/2022
 
 
TXT FDA Proposes More Comprehensive IND Reports
12/08/2022
 
 
TXT Draft Device Human Factors Guidance
12/08/2022
 
 
TXT Comments on Pediatric Clinical Pharmacology Draft
12/08/2022
 
 
TXT FDA Manuscript in the Works on Trial Diversity Strategy
12/08/2022
 
 
TXT FDA Urges Oncopeptides to Withdraw Multiple Myeloma Drug
12/07/2022
 
 
TXT FDA Accelerated Approvals Down This Year: AP
12/07/2022
 
 
TXT FDA Denies Homeopathy Petition
12/07/2022
 
 
TXT Significant HCT/P Deviations at Cryos International
12/07/2022
 
 
TXT FDA Denies Petition on Scrubs as Medical Devices
12/07/2022
 
 
TXT PhRMA Issues with FDA Medical Queries
12/07/2022
 
 
<< Prev  10 11 12 13 14 15 16 17 18 19 20 21 22 23  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving